Switzerland

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Novartis PREVENT Data Show Cosentyx® Helps Patients Realize Early and Lasting Relief In Axial Spondyloarthritis

Lead Product(s): Secukinumab

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 04, 2020

Details:

Phase III PREVENT data show Cosentyx® 150 mg provided significant and sustained improvement in signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA) up to Week 521.

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Novartis Announces Data Showing Jakavi® (Ruxolitinib) More Effective Than Best Available Therapy in Acute Graft-Versus-Host Disease

Lead Product(s): Ruxolitinib

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 22, 2020

Details:

Data from Phase III REACH2 study demonstrate Jakavi can improve outcomes for patients with acute graft-versus-host disease (GvHD) who do not respond to first-line steroid treatment.

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Novartis Cosentyx® gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum

Lead Product(s): Secukinumab

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 27, 2020

Details:

The positive opinion of Cosentyx is based on efficacy and safety outcomes from the PREVENT Phase III study which met the primary endpoint, achieving statistically significant improvements vs placebo.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Novartis Pharmaceuticals Corporation

Novartis PREVENT Data Show Cosentyx® Helps Patients Realize Early and Lasting Relief In Axial Spondyloarthritis

Novartis Pharmaceuticals Corporation

Novartis Announces Data Showing Jakavi® (Ruxolitinib) More Effective Than Best Available Therapy in Acute Graft-Versus-Host Disease

Novartis Pharmaceuticals Corporation

Novartis Cosentyx® gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum